Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Outcome of rhIGF-1/rhIGFBP-3 in ROP (PEDAL)
NCT02386839Phase 2Completed
- Sponsor
- Takeda
- Start
- Mar 2015
- Primary completion
- Sep 2021
- Modality
- Biologic, rProtein (Recombinant Protein)
- Countries
- 6
01
Overview
Phase 2, open-label trial of Premiplex in retinopathy of prematurity (ROP) (2 arms), sponsored by Takeda. Primary endpoints: Visual Acuity, Oculomotor Examination (Motility) and Ocular Alignment and 4 more. Started Mar 2015; status: completed.
02
Drugs
Premiplex
03
Conditions
retinopathy of prematurity (ROP)
Beyond the preview
Go deeper on NCT02386839.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02386839.